The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online

📢2 days to go until the #BTOGSummerMeeting where #LungCancer experts will share the latest updates in the field!

Register now ➡️http://ow.ly/TIQC50JCTgr

Visit http://VJOncology.com for exclusive interviews from the event!

👉https://www.vjoncology.com/event/btog-2022/

#LCsm #NSCLC #Mesothelioma

🎥 Kendall Morrison of @taelifesciences talks on treating glioblastoma with boron neutron capture therapy

Watch: 👉http://ow.ly/ULLC50JO0ym👈

#BNOS2022 @BNOSofficial #BTSM

🎥 @HamounRozati of @imperialcollege talks on assessing stereotactic radiotherapy in patients with high numbers of brain metastases

Watch: 👉http://ow.ly/ZVlE50JO0rN👈

#BNOS2022 @BNOSofficial #BTSM #RadOnc

🎥 John Strickler of @DukeCancer talks on MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer

Watch: 👉http://ow.ly/FB9A50JO0ps👈

@myESMO @ESMOWorldGI #WCGIC22 #CRCsm #ColorectalCancer

longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% ⬇️ risk of death with atezo in adjuvant UC. There’s a strong rationale for circulating rather than tissue biomarkers here. Imvigor011 (randomised III) tests this prospectively

4
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

📢2 days to go until the #BTOGSummerMeeting where #LungCancer experts will share the latest updates in the field!

Register now ➡️http://ow.ly/TIQC50JCTgr

Visit http://VJOncology.com for exclusive interviews from the event!

👉https://www.vjoncology.com/event/btog-2022/

#LCsm #NSCLC #Mesothelioma

🎥 Kendall Morrison of @taelifesciences talks on treating glioblastoma with boron neutron capture therapy

Watch: 👉http://ow.ly/ULLC50JO0ym👈

#BNOS2022 @BNOSofficial #BTSM

🎥 @HamounRozati of @imperialcollege talks on assessing stereotactic radiotherapy in patients with high numbers of brain metastases

Watch: 👉http://ow.ly/ZVlE50JO0rN👈

#BNOS2022 @BNOSofficial #BTSM #RadOnc

🎥 John Strickler of @DukeCancer talks on MOUNTAINEER: Tucatinib plus trastuzumab for HER2+ metastatic colorectal cancer

Watch: 👉http://ow.ly/FB9A50JO0ps👈

@myESMO @ESMOWorldGI #WCGIC22 #CRCsm #ColorectalCancer

longer follow up (3 years) continues to show ctDNA is strongly associated with relapse (HR=6) and a 40% ⬇️ risk of death with atezo in adjuvant UC. There’s a strong rationale for circulating rather than tissue biomarkers here. Imvigor011 (randomised III) tests this prospectively

4
Load More

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter